Story Stocks^®

Abbott Labs (ABT -5%) reported solid Q1 results highlighted by strong revenue growth, but another round of lowered EPS guidance for Q2 and FY26 overshadowed the quarter and validated investor concerns following last quarter's guide-down. ABT projects FY26 comparable sales growth of 6.5% to 7.5%. Of note, the EPS guidance includes $0.20 of dilution related to the recent acquisition of Exact Sciences, a cancer diagnostics company.

• Q1 revenue increased 7.8% yr/yr (+3.7% comparable) to $11.16 bln, exceeding expectations and marking the strongest growth since 2Q22, aided modestly by FX tailwinds and the late-quarter close of the Exact Sciences acquisition. Adjusted EPS delivered a typical modest beat.
• Medical Devices revenue grew 13.2% yr/yr (+8.5% comparable) to $5.54 bln, led by double-digit gains in Electrophysiology, Heart Failure, and Rhythm Management, along with 14.2% growth in continuous glucose monitors.
• Diagnostics revenue rose 6.1% yr/yr (+1.8% comparable) to $2.18 bln, with strength across key regions and contributions from cancer diagnostics, including Cologuard and Cancerguard, partially offset by weaker respiratory testing demand.
• Nutrition remained a weak spot as revenue declined 6.0% yr/yr (-7.7% comparable) to $2.02 bln, though results were slightly ahead of internal expectations as pricing actions begin to stabilize volumes.
• Established Pharmaceuticals revenue increased 13.2% yr/yr (+9.0% comparable) to $1.43 bln, driven by demand in emerging markets.
• The Exact Sciences acquisition, completed March 23, is expected to contribute approximately $3 bln in incremental sales in 2026.

Briefing.com Analyst Insight:

Abbott delivered a good quarter operationally, particularly with strong performance in Medical Devices and a healthy top-line beat, but the investment narrative remains clouded by ongoing earnings pressure. The repeated guidance cuts are difficult to overlook, even with the explanation of acquisition-related dilution and temporary headwinds like a weak respiratory season. While the Exact Sciences acquisition strengthens Abbott's long-term positioning in the fast-growing cancer diagnostics market, it introduces near-term complexity and earnings drag. Meanwhile, continued weakness in Nutrition and sensitivity to FX in Established Pharmaceuticals add to the uncertainty. Until Abbott demonstrates more consistent earnings leverage and clearer benefits from its strategic investments, the stock may remain under pressure despite its solid underlying growth profile.